Blog

Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain market share compared to generics, and new biosimilars do not always lead to lower prices.

Does the introduction of MDR and IVDR mean that we risk losing important medical technology innovations? Do the tightened rules make the certification process so complex that start-up companies simply do not participate and give up, with the result that important innovations that can improve care never reach the market? What can we do in the short term to avoid this happening?

One of the more important aims of the EU pharmaceutical legislation is to ensure access to affordable medicines to all patients in the region. A new product, for example to treat cancer, should be available for all EU patients, including those in the smaller member states.